Grants and Contributions:
Title:
H5N1 -mRNA vaccine for Highly Pathogenic Avian Influenza for Protection of Canadian Livestock
Agreement Number:
1028947
Agreement Value:
$2,128,801.00
Agreement Date:
Jun 1, 2024 - Jul 1, 2026
Description:
This proposal aims to develop a made-in-Canada solution to the threat posed by Highly Pathogenic Avian Influenza (HPAI) to Canadian livestock. Providence Therapeutics will initiate work to design and develop an mRNA vaccine drug candidate for a relevant strain using their mRNA and INTENT lipid nanoparticle (LNP) platforms.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Calgary, Alberta, CA T2J 3J1
Reference Number:
172-2024-2025-Q4-1028947
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
738045079
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 119 days. The total amended value is 344,986 dollars.
Amendment Date
Mar 31, 2026
Recipient's Legal Name:
Providence Therapeutics Holdings Inc.
Federal Riding Name:
Calgary Midnapore
Federal Riding Number:
48008
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
3254
Amendments: